
Aktiviere Job-Benachrichtigungen per E-Mail!
Erstelle in nur wenigen Minuten einen maßgeschneiderten Lebenslauf
Überzeuge Recruiter und verdiene mehr Geld. Mehr erfahren
A leading biotechnology company in Berlin seeks a Director of Market Access to develop and implement strategies for oncology product reimbursement and pricing. The ideal candidate will have 7-10 years of experience in market access, a Master's degree in a relevant field, and fluency in German and English. This role involves collaboration with various teams and stakeholders to ensure sustainable access to innovative therapies. Join a dedicated team making an impact in cancer treatment while fostering a culture of innovation.
At Genmab, we are dedicated to building extraordinary futures, together, by developing antibody products and groundbreaking, knock-your-socks-off KYSO antibody medicines that change lives and the future of cancer treatment and serious diseases. We strive to create, champion and maintain a global workplace where individuals’ unique contributions are valued and drive innovative solutions to meet the needs of our patients, care partners, families and employees.
Our people are compassionate, candid, and purposeful, and our business is innovative and rooted in science. We believe that being proudly authentic and determined to be our best is essential to fulfilling our purpose. Yes, our work is incredibly serious and impactful, but we have big ambitions, bring a ton of care to pursuing them, and have a lot of fun while doing so.
Does this inspire you and feel like a fit? Then we would love to have you join us!
As Genmab advances toward commercialization in Europe, this position will play a pivotal role in shaping the company’s success in the German market. The Director, Market Access (Germany) is responsible for developing and executing strategies to ensure optimal market access, reimbursement, and pricing outcomes for Genmab’s oncology portfolio. This role requires strong expertise in market access and health economics, as well as effective collaboration with regional and global teams in Medical Affairs, Regulatory Affairs, Commercial Operations, and Corporate Affairs, and engagement with HTA bodies, payers, policymakers, and key external stakeholders.
Genmab maximizes the efficiency of an agile working environment, when possible, for the betterment of employee work‑life balance. Our offices are crafted as open, community‑based spaces that work to connect employees while being immersed in our powerful laboratories. Whether you’re in one of our office spaces or working remotely, we thrive on connecting with each other to innovate.
Genmab is an international biotechnology company with a core purpose to improve the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its hard‑working, innovative and collaborative team has invented next‑generation antibody technology platforms and harnessed translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T‑cell engagers, antibody‑drug conjugates, next‑generation immune checkpoint modulators and effector function‑enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock‑Your‑Sock‑Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Genmab is committed to protecting your personal data and privacy. Please see our privacy policy for handling your data in connection with your application on our website Job Applicant Privacy Notice (genmab.com).
Please note that if you are applying for a position in the Netherlands, Genmab’s policy for all permanently budgeted hires in NL is initially to offer a fixed‑term employment contract for a year, if the employee performs well and if the business conditions do not change, renewal for an indefinite term may be considered after the contract.